Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idenix Targets HIV Partner By Year End

This article was originally published in The Pink Sheet Daily

Executive Summary

IDX899 boasts positive Phase I/II prospects and potential as a fixed-dose combo.
Advertisement

Related Content

GSK Pays $34 Million Upfront To License Idenix’s Phase II HIV Candidate
GSK Pays $34 Million Upfront To License Idenix’s Phase II HIV Candidate
Ardea’s HIV Drug Shows Once-Daily Potential In Phase II
Ardea’s HIV Drug Shows Once-Daily Potential In Phase II
Idenix Restructures Under Amended Deal With Novartis
Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate
Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate

Topics

Advertisement
UsernamePublicRestriction

Register

PS067673

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel